A Study of MK0359 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0359-016)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 2

Conditions: Pulmonary Disease, Chronic Obstructive

Treatments: Drug: MK0359

Study type: Interventional

Funder types: Industry

Identifiers

NCT00482235

2007_569

0359-016

Details and patient eligibility

About

A study to test the effect of MK0359 in lessening the symptoms of COPD as compared to salmeterol and placebo.

Enrollment: 45 patients

Sex: All

Ages: 40 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• You are between the ages of 40 and 75
• You have had a history for at least a year of COPD symptoms
• You have a history of smoking one pack of cigarettes per day for 10 years

Exclusion criteria

• You have been in a research study with an investigational drug or vaccine in the last 4 weeks.
• You have donated blood in the last 4 weeks.
• You have been hospitalized or had major surgery in the last 4 weeks
• You have been treated in the emergency room within the last 2 months or hospitalized within the last 3 months for your COPD symptoms
• You have a history of heart problems in the last 6 months
• You have a history of stomach problems
• You are unwilling to avoid grapefruit juice throughout the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind